| Investor | Value | Of portfolio | Shares | Change | Quarter |
|---|---|---|---|---|---|
| Renaissance Technologies | $349.7K | 0.00% | 26.80K | New | Q2 2026 |
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a EIKN trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Sep 2, 2026 | Column Group Iv Gp, LpBeneficial Owner of more than 10% of a Class of Security | Purchase at price 11.56 per share. | 89.2K | $1.03M |
| Feb 5, 2026 | Column Group L.P.Beneficial Owner of more than 10% of a Class of Security | Purchase at price 14.50 per share. | 2.12M | $30.71M |
| Feb 5, 2026 | Column Group Iv Gp, LpBeneficial Owner of more than 10% of a Class of Security | Purchase at price 14.50 per share. | 2.12M | $30.71M |
| Feb 5, 2026 | Perlmutter Roger MChief Executive Officer | — | 284.9K | — |
| Feb 5, 2026 | Column Group L.P.Beneficial Owner of more than 10% of a Class of Security | — | 3.60M | — |
| Feb 5, 2026 | Wolfe JoshDirector and Beneficial Owner of more than 10% of a Class of Security | — | 5.70M | — |
| Feb 5, 2026 | Column Group Iv Gp, LpBeneficial Owner of more than 10% of a Class of Security | — | 3.60M | — |
| Feb 5, 2026 | Lux Venture Partners V, LlcBeneficial Owner of more than 10% of a Class of Security | — | 5.70M | — |
| Feb 3, 2026 | Frazier Kenneth CDirector | Purchase at price 18.00 per share. | 111.1K | $2.00M |
| Feb 3, 2026 | Foresite Capital Management Iv, L.L.C.Beneficial Owner of more than 10% of a Class of Security | Purchase at price 18.00 per share. | 55.6K | $999.99K |
| Feb 3, 2026 | Wolfe JoshDirector and Beneficial Owner of more than 10% of a Class of Security | Purchase at price 18.00 per share. | 277.8K | $5.00M |
| Feb 3, 2026 | Lux Venture Partners V, LlcBeneficial Owner of more than 10% of a Class of Security | Purchase at price 18.00 per share. | 277.8K | $5.00M |
| Feb 3, 2026 | Foresite Capital Management Iv, L.L.C.Beneficial Owner of more than 10% of a Class of Security | — | 4.04M | — |
Eikon Therapeutics, Inc., operates as a clinical biopharmaceutical company in the United States. It develops medicines to address serious unmet medical needs. Its products include EIK1001, a systemically administered TLR 7/8 dual-agonist designed to activate innate and adaptive immune anti-tumor responses; EIK1003 and EIK1004, which are selective PARP1 inhibitors in ovarian, breast, prostate, and pancreatic cancers and, specifically with the brain-penetrant; EIK1004 to address brain metastases and primary brain malignancies; EIK1005, a potent WRN helicase inhibitor and anti-tumor agent for MSI-high tumors; and EIK1006, a clinical candidate and next-generation androgen receptor antagonist with activity against multiple clinically emergent variants of androgen receptor. The company was incorporated in 2019 and is based in Millbrae, California.
Buy / hold / sell counts